Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 27, 2013. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 716,000 Ordinary Shares of 25 pence each.
- Purchase Date: August 27, 2013.
- Price Range: Highest price paid was 1,683.00 pence per share; lowest price paid was 1,658.00 pence per share.
- Treasury Holdings (Settled): 512,652,412 shares (9.47% of total issued share capital).
- Treasury Holdings (Including Unsettled): 514,835,412 shares (10.51% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,900,722,930 shares.
Material Changes
The filing reports an increase in the Company's treasury share holdings following the purchase of 716,000 shares. Consequently, the percentage of total voting rights held in treasury increased to 10.51% when including unsettled purchases. No other material changes to operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or discussion of risks and contingencies. It is a compliance disclosure regarding share repurchases and voting rights calculations under the Financial Conduct Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of shares in issue (4,900,722,930) to confirm voting thresholds for regulatory notifications.
- Confirm the current treasury share percentage (10.51% including unsettled) against the company's authorized buyback limits.
- Note that the 716,000 shares purchased are intended to be held in Treasury.